Dental products company Envista Holdings (NYSE: NVST) met Wall Street’s revenue expectations in Q3 2026, with sales up 3.2% year on year to $691.5 million. Its non-GAAP profit of $0.40 per share was 12.4% above analysts’ consensus estimates.

Is now the time to buy NVST? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Envista’s latest quarter reflected stable demand in core dental markets but was overshadowed by ongoing macroeconomic uncertainty, particularly in the U.S. and China. Management noted that insurance-covered categories like prevention and diagnostics remained resilient, while elective areas such as ortho and implants lagged historical growth. CEO Paul Keel attributed the company’s margin expansion to continued factory and general administrative productivity, despite China’s sales contraction due to value-based procurement (VBP) preparations. “We converted good top-line performance into even stronger earnings growth,” Keel said, adding that strong free cash flow supported ongoing share repurchases this quarter.

Looking forward, Envista’s raised profit guidance is driven by new product launches, ongoing operational efficiency, and the expectation that VBP-related disruptions in China will subside in the first half of next year. Management emphasized the importance of commercializing recent product investments and expanding their reach, particularly in diagnostics and clear aligners. CFO Eric Hammes noted the company is keeping a close watch on global dental procedure volumes and the potential for further moderation in pricing trends, adding, “We expect dental inflation to return to historical levels as we move into 2027.”

Key insights from management’s remarks

Management identified stable performance in developed markets, ongoing innovation, and operational productivity as key drivers, while China’s VBP process and U.S. demand softness remained notable headwinds.

• Developed markets steady: Envista reported mid-single-digit growth in developed regions, with Europe and North America both contributing, though North America’s pace was slower due to macro uncertainty impacting patient and clinician confidence.
• China VBP headwinds: The company experienced a low double-digit revenue decline in China, as the market prepared for government value-based procurement (VBP) reforms. This led to inventory drawdowns, especially in orthodontics, and management expects VBP price cuts to weigh on margins when fully implemented next year.
• Product innovation momentum: Recent launches such as NOMAD Pro 3 (handheld X-ray), Ultra HDL Prismatic Loupe, and the AI-powered Endo Module for DTX Studio drove growth, with management highlighting early positive market feedback and increased clinician adoption.
• Diagnostics and Spark growth: The diagnostics business saw solid expansion across hardware, software, and services, supported by new offerings and integrated workflows. The Spark clear aligner line grew high single digits, outpacing broader market growth and gaining share in key regions, including a rapid launch in Japan.
• Operational productivity gains: Envista’s price, procurement, and factory productivity efforts more than offset inflationary pressures, enabling margin expansion and allowing continued investment in R&D and commercial capabilities.

Drivers of future performance

Envista’s near-term outlook is shaped by new product commercialization, stabilization in China, and moderating price trends across global dental markets.

• Commercialization of new products: Management emphasized scaling recently launched products—particularly in implants, diagnostics, and clear aligners—as essential for sustaining momentum. Broader adoption and successful market entry, especially in Japan for Spark, are expected to drive incremental revenue.
• China VBP and margin headwinds: The full impact of China’s value-based procurement reforms will be felt next year, resulting in steep price reductions (up to 50% in ortho and 10–15% in implants). While management expects to gain market share and volume, these changes will create margin pressure, particularly within China, though they anticipate margin expansion company-wide driven by operational improvements elsewhere.
• Pricing normalization and market dynamics: The company expects dental inflation and price increases to moderate to traditional levels (1–1.5% annually), following a period of higher-than-usual price growth linked to tariffs and inflation. Management is monitoring U.S. and global dental procedure volumes for signs of further demand shifts.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will monitor (1) the pace and breadth of new product adoption, especially for Spark and diagnostics, (2) the rollout and impact of China’s VBP reforms on both revenue and margins, and (3) stabilization or improvement in U.S. and European dental procedure volumes. Execution on commercialization and the ability to offset margin headwinds from China will be crucial to achieving guidance.

Envista currently trades at $24.89, down from $27.25 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Stocks that trumped tariffs

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.